Advanced Lung Cancer

EMA backs datopotamab deruxtecan for advanced lung cancer

EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.